HIV Oral Drug Composition Patent
Summary
The USPTO granted Patent US12594244B2 to Gilead Sciences, Inc. covering a solid oral dosage form combining tenofovir alafenamide, emtricitabine, and a compound of Formula I for HIV treatment. The patent contains 29 claims and was granted on April 7, 2026, with a filing date of September 29, 2025.
What changed
The USPTO granted Patent US12594244B2 to Gilead Sciences for a therapeutic composition comprising tenofovir alafenamide, emtricitabine, and a compound of Formula I in a solid oral dosage form. The patent names inventors Benjamin Micah Collman, Lei Hong, and Joanna M. Koziara. This grant provides Gilead with exclusive rights to this specific HIV treatment formulation in the United States.
Pharmaceutical companies developing generic HIV treatments or similar fixed-dose combinations should review this patent for freedom-to-operate considerations. Competitors seeking to develop alternative oral HIV therapies should ensure their formulations do not infringe the 29 claims. No immediate compliance deadline applies as this is a patent grant rather than a regulatory requirement.
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Therapeutic compositions for treatment of human immunodeficiency virus
Grant US12594244B2 Kind: B2 Apr 07, 2026
Assignee
Gilead Sciences, Inc.
Inventors
Benjamin Micah Collman, Lei Hong, Joanna M. Koziara
Abstract
A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
CPC Classifications
A61K 9/209 A61K 9/0053 A61K 9/2013 A61K 9/2027 A61K 9/2054 A61K 9/2086 A61K 9/2095 A61K 9/28 A61K 9/2833 A61K 31/513 A61K 31/5365 A61K 31/537 A61K 31/553 A61K 31/675 A61P 31/18
Filing Date
2025-09-29
Application No.
19343371
Claims
29
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.